J. Marty

发表

Molecular determinants of differential sensitivity to docetaxel and paclitaxel in human pediatric cancer models.

A. Tolcher, G. Mangold, D. Campos, 2006, Anticancer research.

Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model.

E K Rowinsky, S G Hilsenbeck, D. V. Von Hoff, 2000, European journal of cancer.

Understanding the outcomes of a home nursing programme for patients with epidermolysis bullosa: an Australian perspective

Z. Kopecki, A. Cowin, J. Marty, 2016, International wound journal.

Water soluble 20(S)-glycinate esters of 10,11-methylenedioxycamptothecins are highly active against human breast cancer xenografts.

D. V. Von Hoff, G. Mangold, P. Potter, 1999, Cancer research.

Squalamine treatment of human tumors in nu/nu mice enhances platinum-based chemotherapies.

D. V. Von Hoff, M. Zasloff, K. Holroyd, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer

C. Begley, J. Rasko, C. Begley, 1996, The Lancet.

Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer.

C. Begley, J. Zalcberg, I. Davis, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Enhancement o f P latelet R ecovery A fter M yelosuppressive Chemotherapy b y R ecombinant H uman M egakaryocyte Growth a nd D evelopment F actor i n P atients With A dvanced C ancer

Michael R. Green, C. Begley, J. Zalcberg, 2000 .

Pharmacokinetic Analysis of Pegylated Megakaryocyte Growth and Development Factor in Humans

C. Begley, J. Cebon, L. Roskos, 2000, Growth factors.

Thrombopoietin measurement in thrombocytosis: dysregulation and lack of feedback inhibition in essential thrombocythaemia

J. Marty, C. Kelly, J. Nichol, 1997, British journal of haematology.

Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor.

C. Begley, J. Collins, J. Szer, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Elevated expression of DNA ligase I in human cancers.

D. Sun, J. Marty, S. Weitman, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Preclinical Antitumor Activity and Pharmacokinetics of Methyl-2-Benzimidazolecarbamate (FB642)

D. V. Von Hoff, G. Mangold, D. Dexter, 2002, Investigational New Drugs.

The new dioxolane, (-)-2'-deoxy-3'-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts.

D. V. Von Hoff, J. Jolivet, J. Marty, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.

E K Rowinsky, S G Hilsenbeck, D. V. Von Hoff, 1999, Cancer research.

Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim

S. Durrant, I. Lewis, J. Marty, 2003, Bone Marrow Transplantation.

Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft

D. V. Von Hoff, S. Hilsenbeck, G. Mangold, 1999, Cancer Chemotherapy and Pharmacology.

MGI 114: augmentation of antitumor activity when combined with topotecan.

D. V. Von Hoff, S. Hilsenbeck, J. Marty, 2000, Journal of pediatric hematology/oncology.